Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System

There is a growing population of new users of glucagon-like peptide-1 receptor agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA products approved for treatment of type 2 diabetes (T2D) or for weight management the United States (U.S.) This poster summarizes a study that described the characteristics of initiators of GLP-1RA and GIP/GLP-1RA products in the U.S., focusing on approved indications for weight management and for T2D. It was presented at the 2025 ISPE Annual Meeting.